WallStSmart

Novartis AG ADR (NVS)vsUroGen Pharma Ltd (URGN)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 22822% more annual revenue ($57.36B vs $250.25M). NVS leads profitability with a 17.5% profit margin vs -26.3%. NVS earns a higher WallStSmart Score of 48/100 (D+).

NVS

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 9.0Value: 2.7Quality: 4.5
Piotroski: 4/9Altman Z: 1.96

URGN

Avoid

31

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -7.59
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-67.6%)

Margin of Safety

-67.6%

Fair Value

$95.76

Current Price

$160.50

$64.74 premium

UndervaluedFair: $95.76Overvalued

Intrinsic value data unavailable for URGN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS4 strengths · Avg: 9.3/10
Market CapQuality
$302.86B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
34.0%10/10

Strong operational efficiency at 34.0%

Return on EquityProfitability
26.9%9/10

Every $100 of equity generates 27 in profit

Free Cash FlowQuality
$4.76B8/10

Generating 4.8B in free cash flow

URGN2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
223.9%10/10

Revenue surging 223.9% year-over-year

Debt/EquityHealth
-1.5710/10

Conservative balance sheet, low leverage

Areas to Watch

NVS4 concerns · Avg: 4.0/10
P/E RatioValuation
30.6x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.1x4/10

Trading at 8.1x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

URGN4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.28B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-1481.0%2/10

ROE of -1481.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.0%.

Bull Case : URGN

The strongest argument for URGN centers on Revenue Growth, Debt/Equity. Revenue growth of 223.9% demonstrates continued momentum.

Bear Case : NVS

The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.

Bear Case : URGN

The primary concerns for URGN are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

NVS profiles as a value stock while URGN is a hypergrowth play — different risk/reward profiles.

URGN carries more volatility with a beta of 1.64 — expect wider price swings.

URGN is growing revenue faster at 223.9% — sustainability is the question.

NVS generates stronger free cash flow (4.8B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (48/100 vs 31/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

UroGen Pharma Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

UroGen Pharma Ltd (URGN) is an innovative biotechnology company focused on the development of advanced therapies for urological diseases, including urothelial carcinoma and bladder cancer. Leveraging its proprietary reverse thermal gel technology, the company enables targeted, sustained drug delivery, maximizing treatment efficacy while reducing systemic side effects. UroGen's strong clinical pipeline underscores its commitment to addressing substantial unmet medical needs in the oncology space, positioning the company as a potential leader in the urological oncology market and significantly improving patient outcomes.

Want to dig deeper into these stocks?